Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling.
OBJECTIVE
To assess the consequences to mother and baby of abruptly discontinuing antidepressant or benzodiazepine medication during pregnancy and to assess the impact of our counselling.


METHODS
All women who consulted the Motherisk Program between November 1996 and December 1997 and who stopped taking antidepressant or benzodiazepine medication when pregnancy was confirmed agreed to participate in the study.


METHODS
Subjects were interviewed, received counselling, and completed a questionnaire 1 month after their initial call and after the birth of their baby.


RESULTS
Of 36 women who completed the study, 34 discontinued their medication abruptly for fear of harming the fetus, 28 on the advice of their physician; 26 (70.3%) women reported physical and psychological adverse effects, 11 reported psychological effects only, and 11 reported suicidal ideation (4 were admitted to hospital). After counselling, 22 of 36 (61.1%) women resumed taking their medication, and 4 found that they no longer required it. One woman had a therapeutic abortion and 2 experienced spontaneous abortions; there were therefore 35 healthy babies (including 2 sets of twins) born to 33 women; 14 of 21 mothers breast-fed their babies while taking their psychotropic medication, with no adverse effects reported.


CONCLUSIONS
When assessing the risks and benefits of taking psychotropic medication during pregnancy, women and their physicians should be aware that the abrupt discontinuation of psychotropic drugs can lead to serious adverse effects. Counselling is effective in reassuring women to adhere to therapy.
Einarson
A
A
Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hospital for Sick Children, 555 University Ave., Toronto ON 5G 1X8. einarson@sickkids.on.ca
Selby
P
P
Koren
G
G
D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects; D000928:Antidepressive Agents / Q000009:adverse effects; D003376:Counseling; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced / Q000523:psychology*; D011619:Psychotropic Drugs / Q000009:adverse effects*; D012307:Risk Factors; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D013723:Teratogens
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D011619:Psychotropic Drugs; D013723:Teratogens